Advaxis Inc. buy stratec
Summary
This prediction ended on 03.12.18 with a price of €5.55. The BUY prediction by stratec for Advaxis Inc. performed very badly with a performance of -86.69%. stratec has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Advaxis Inc. | - | - | - | - |
iShares Core DAX® | 1.395% | -0.272% | 17.642% | 15.576% |
iShares Nasdaq 100 | 2.287% | 6.912% | 37.651% | 51.525% |
iShares Nikkei 225® | 1.617% | 3.038% | 12.910% | 8.243% |
iShares S&P 500 | 0.659% | 3.687% | 29.434% | 44.236% |
Comments by stratec for this prediction
In the thread Advaxis Inc. diskutieren
stratec stimmt der Buy-Einschätzung von tamam zu
stratec stimmt am 24.01.2018 der Buy-Einschätzung von tamam mit dem Kursziel 10$ zu.
Überschrift: ADXS has very interesting make-or-break potential, caveat emptor!
Tolerability of ADXS11-001 Lm-LLO Listeria Based Immunotherapy With Mitomycin, Fluorouracil and Radiation for Anal Cancer
ADXS reports that 8 of 9 patients were progression-free at the 42 months mark. If researchers could reproduce this in a wider patient population, then addition of the Lm-based immunotherapy might represent a new standard of care.